England (Commonwealth Union) – Melanoma is one of the most invasive cancers and a discovery for reprogramming our immune cells to shrink or kill off cancer cells has demonstrated to be effective in the otherwise difficult to treat skin cancer, melanoma. The findings led by the University of Bristol was published in Advanced Science showing a new way to clear early stage pre-cancerous as well as late-stage tumor cells.
Applying minuscule artificial capsules known as protocells designed to move reprogramming cargoes taken up by inflammatory cells, Researchers revealed that they were capable of transforming these cells into a state, which makes them greatly effective at decelerating growth and destroying of melanoma cells. It was demonstrated to be effective in animal and human immune cells.
Researchers for the first time tested the capacity of a protocell to deliver cargoes for reprogramming immune cells paving the way for a potential novel target for the production of cancer immunotherapies.
A lead author of the study, Paul Martin, Professor of Cell Biology in the School of Biochemistry at the University of Bristol said: “Our immune cells have a surveillance capacity which enables them to detect pre-cancerous cells arising at any tissue site in the body. However, when immune cells encounter cancer cells, they are often subverted by the cancer cells and instead tend to nourish them and encourage cancer progression. We wanted to test whether it might be possible to reprogramme our immune system to kill these cells rather than nurture them.”
Researchers initially tested the proof of concept in zebrafish larvae, which are ideal as they allow light to pass through, giving scientists the ability to see inflammatory immune cells interact with cancer cells which we are incapable of doing for our own tissues.
Protocells loaded with anti-miR223 molecules that connect and hinder signaling machinery in inflammatory immune cells, work by successfully extending their pro-inflammatory state, seen driving altered immune cell-cancer cell engagements, decelerating cancerous cell growths and driving elevated larvae tumor cell deaths.
